Are Small Strokes Really Caused By Clogged Arteries? New Study Says No.

If you or a loved one has ever been told you have “chronic small vessel ischemic changes” on a brain scan, or if you have experienced a lacunar stroke, you have likely been given the standard advice: watch your cholesterol, take a statin, and manage your blood pressure.

But what if the standard advice is missing the real problem?

A groundbreaking new study published in a leading stroke journal challenges decades of conventional wisdom. It turns out that for many people, the driver of small strokes and progressive brain damage is not fatty plaque clogging the arteries—but something entirely different.

The real culprit? Enlarged, damaged, and stretched brain arteries—a condition known as dolichoectasia—that transmit destructive pulsations deep into the brain, silently destroying small vessels and laying the groundwork for dementia, gait problems, and cognitive decline.

This article unpacks the study’s findings, explains why this matters for you or your loved ones, and offers practical, evidence-based strategies—including the overlooked role of postprandial glucose and nutritional support like black garlic—that may help protect your brain.

The Surprising Answer: It’s Not About Plaque

Researchers divided the patients into two groups: those with lacunar strokes (small, deep infarcts caused by damage to tiny penetrating arteries) and those with non-lacunar strokes (typically caused by larger-artery blockages or emboli, or blood clots from the heart).

They then looked for two distinct types of large-artery disease:

Pathology	Definition	What It Represents
Large-Artery Stenosis (LAS)	≥50% narrowing of intracranial or cervical arteries	Classic atherosclerosis—plaque buildup
Dolichoectasia	Abnormal elongation, tortuosity, and widening of arteries (especially the basilar artery)	Degenerative breakdown of the arterial wall

Here is where the results became striking:

Large-artery stenosis was associated with a lower odds of lacunar stroke and showed no relationship with cSVD markers, incident infarcts, or white matter progression. In other words, plaque-clogged arteries were not driving the small-vessel disease.
Basilar artery dolichoectasia, on the other hand, was powerfully associated with:
- 4.67 times higher odds of lacunar stroke
- 2.57 times higher cSVD burden scores
- 2.29 times higher odds of new silent infarcts over one year (75% of which were subcortical)
- Greater progression of white matter hyperintensities

The study authors concluded:

“cSVD, including lacunar stroke, was unrelated to large-artery stanosis but strongly associated with dolichoectasia and wider arteries. These findings support a nonatheromatous, intrinsic microvascular pathology, particularly segmental arteriolar disorganization, as the principal mechanism.”

In plain language: the primary problem is not fatty plaque clogging pipes. It is the pipes themselves becoming damaged, stretched, and structurally unstable.

Why This Answer Changes Everything

This study is significant for several reasons:

It challenges the cholesterol-centric model for a large portion of stroke patients. Many patients with lacunar strokes have normal cholesterol levels and no significant carotid stenosis—yet they continue to progress.
It explains the “missing link” between large-artery stiffness and microvascular brain damage. Dolichoectasia appears to be the mechanical transmitter that channels destructive pulsatile energy from the aorta and carotids directly into the fragile perforating arterioles deep within the brain.
It calls for mechanism-specific therapies. If the root cause is not atherosclerosis, then statins and antiplatelet agents may be insufficient. We need strategies that target the structure and elasticity of the arterial wall itself.

So What If I Have a Lacunar Stroke? (Spoiler: It Matters)

It is a common and dangerous misconception to dismiss lacunar strokes as “small” or “silent.” After all, the word lacune comes from the Latin for “lake” or “cavity”—implying a tiny, empty space. But make no mistake: these are not benign events.

Here is why every lacunar stroke and each increment of white matter hyperintensity (WMH) matters profoundly:

1. The Accumulation Effect: Death by a Thousand Cuts

A single lacunar infarct may produce no noticeable symptoms if it occurs in a “silent” area of the brain. However, cerebral small-vessel disease (cSVD) is a chronic, progressive condition. Over years, these small infarcts accumulate.

Each new infarct destroys a small cluster of neurons and their connections.
As the burden grows, the brain loses its cognitive reserve—the buffer that allows it to function despite damage.
Eventually, the cumulative effect crosses a threshold, and what was once “silent” becomes clinically devastating.

If you or a loved one has ever had a CT scan of the head, you have likely seen the words “chronic small vessel ischemic changes” or “age-related white matter changes” on the radiology report.

That is not incidental wallpaper text—it is the radiological footprint of accumulated microvascular damage.

In the elderly, these findings are so common that they are often dismissed as “normal for age.” But “common” does not mean “harmless.”

Each of those tiny bright spots on the scan represents real, irreversible loss of brain tissue and connectivity. This study demonstrates that this damage is not static—it progresses measurably over just one year in patients with dolichoectasia, meaning what looks stable on one scan may be quietly worsening beneath the surface.

2. The Dementia Connection (Vascular Cognitive Impairment)

This is perhaps the most critical “so what.” cSVD is now recognized as the leading vascular contributor to dementia, second only to Alzheimer’s disease in overall prevalence.

The white matter hyperintensities (WMHs) seen on MRI—which this study showed progressed significantly in patients with dolichoectasia—represent actual damage to the brain’s “telephone lines.”
These WMHs disrupt the neural networks that govern executive function, processing speed, and memory.
Over time, patients with progressive cSVD develop vascular cognitive impairment, which can range from mild sluggishness in thinking to full-blown vascular dementia. In fact, up to 45% of dementia cases have a significant vascular component, and cSVD is the primary driver.

3. Gait Disturbances and Physical Decline

The penetrating arterioles affected by cSVD supply the basal ganglia and deep white matter—regions critically involved in motor control. As these areas accumulate damage, patients develop:

Slower gait speed (often the first noticeable sign)
Balance problems and an increased risk of falls
Parkinsonian features (rigidity, shuffling steps) without true Parkinson’s disease

These physical changes strip away independence long before dementia sets in.

4. Mood Disorders and Apathy

Damage to the frontal-subcortical circuits—which are highly vulnerable to cSVD—frequently manifests as:

Vascular depression (depression that is often resistant to standard SSRIs)
Apathy and loss of motivation
Emotional lability (sudden mood swings)

These symptoms are frequently misattributed to “just getting older” or primary psychiatric illness, when in reality, they are direct consequences of microvascular brain damage.

5. Increased Risk of Future Catastrophic Stroke

The presence of cSVD and lacunes is not an endpoint; it is a powerful predictor of future, larger strokes.

Damaged small vessels compromise the brain’s autoregulation—its ability to maintain stable blood flow.
When a larger embolic or thrombotic event occurs, the brain with extensive cSVD has far less collateral reserve to survive the insult.
In essence, cSVD sets the stage for a more severe stroke to become a major disabling or fatal event.

6. The Hidden Economic and Caregiver Burden

Unlike a single, dramatic large-vessel stroke that prompts immediate rehabilitation, the slow creep of cSVD often goes unacknowledged until a patient can no longer manage finances, drive safely, or live independently.

The gradual nature of cognitive and physical decline places a prolonged, exhausting burden on caregivers and families.
It leads to earlier nursing home placement than many other chronic conditions.

The Bottom Line:
A lacunar stroke is not a “pass” from serious neurological disease. It is a canary in the coal mine—an early warning sign that the brain’s microcirculation is failing.

The study we are discussing shows that dolichoectasia drives the progression of this disease (evidenced by new infarcts and growing white matter hyperintensities over just one year). Ignoring it is not an option if we wish to preserve cognitive function, mobility, and quality of life into old age.

What Causes Enlarged, Damaged Brain Arteries?

If dolichoectasia is not caused by plaque, what drives it? The study does not fully answer this, but the broader vascular biology literature points to a clear set of mechanisms:

The Primary Driver: Degenerative Wall Failure

The arterial wall is composed of three layers. The middle layer—the tunica media—is rich in elastin, a protein that provides recoil and maintains vessel shape under pulsatile pressure.

Over time, several factors degrade this elastin matrix:

Factor	Mechanism
Chronic hypertension	Increases pulsatile stress, mechanically fatiguing elastin fibers
Matrix Metalloproteinases (MMPs)	Enzymes that literally chew up elastin and collagen—especially MMP-2 and MMP-9
Oxidative stress	Generates free radicals that damage the internal elastic lamina and activate MMPs
Advanced Glycation End-products (AGEs)	Cross-link collagen, making arteries stiff and less compliant, which in turn increases pulsatile stress (a vicious cycle)
Chronic low-grade inflammation	Drives MMP expression and perpetuates wall degeneration
Genetic predisposition	Variations in genes coding for elastin, fibrillin, and other matrix proteins can predispose individuals to earlier and more severe wall failure

The Overlooked Driver: Insulin Resistance and Blood Sugar Spikes

While the table above lists oxidative stress and AGEs as distinct mechanisms, it is critical to understand what drives them in a large portion of the population: recurrent hyperglycemia due to insulin resistance.

This is not just a concern for diagnosed diabetics. Millions of adults with prediabetes, metabolic syndrome, or simply poor postprandial or after-meal glucose control experience daily glucose spikes—often without ever having a fasting glucose or HbA1c level that would trigger a diabetes diagnosis.

Each of these glucose excursions:

Generates a burst of reactive oxygen species (ROS), directly damaging the internal elastic lamina
Promotes the formation of AGEs, which cross-link collagen and stiffen the arterial wall
Upregulates MMP-2 and MMP-9, accelerating elastin degradation
Creates a pro-inflammatory state that perpetuates vascular remodeling

In other words, even “prediabetic” glucose levels are sufficient to drive the very same oxidative and glycative damage that leads to arterial wall degeneration and, ultimately, dolichoectasia. The damage accumulates silently over decades, long before any formal diagnosis is made.

This is precisely why metabolic health is not just about preventing diabetes—it is about preserving the structural integrity of the brain’s blood vessels. And it is why interventions that stabilize glucose and reduce postprandial spikes, such as dietary modification and targeted nutraceuticals like black garlic/SAC, may play a direct role in preventing the vascular cascade that leads to lacunar strokes and dementia.

Key Clinical Implication:

This means that insulin resistance—even without a formal diagnosis of diabetes—is a direct contributor to arterial wall degradation and dolichoectasia. Millions of adults with metabolic syndrome, prediabetes, or simply elevated postprandial glucose levels are accumulating silent vascular damage that may eventually manifest as lacunar strokes, white matter disease, and cognitive decline.

This is precisely where black garlic and SAC become even more relevant: S-allylcysteine has been shown to:

Reduce postprandial glucose excursions
Directly scavenge the ROS generated by glucose spikes
Inhibit AGE formation
Suppress MMP activity induced by hyperglycemic conditions

In other words, SAC addresses the metabolic trigger of arterial wall degeneration, not just the hemodynamic one.

The Hemodynamic Amplifier: Pulse Wave Velocity (PWV)

As the aorta stiffens with age (increasing pulse wave velocity), the reflected pulse wave returns to the central circulation earlier, striking the basilar artery and intracranial vessels with greater force.

Because these vessels are suspended in cerebrospinal fluid without external structural support, they are uniquely vulnerable to this repeated mechanical assault. They gradually dilate, elongate, and become tortuous—the very definition of dolichoectasia.

Once dolichoectasia develops, it no longer dampens the pulse wave; instead, it transmits high-energy pulsations directly into the downstream, tiny penetrating arteries called arterioles.

The results are microtears, wall thickening, and structural breakdown of the tiny branching vessels that the study describes as the final common pathway to lacunar strokes and white matter disease.

In simpler terms: the large, floppy artery acts like a cracked whip, sending damaging shockwaves into the delicate, downstream pipes that supply deep brain tissue.

Over time, these tiny vessels lose their ability to regulate blood flow, leak fluid into surrounding brain tissue, and eventually collapse or rupture—manifesting as the white spots on MRI and the small cavities we call lacunes.

Is There a Solution? Emerging Evidence for Black Garlic and SAC

Here is where we bridge the gap between the study’s sobering findings and an actionable nutritional strategy.

The study’s authors lament that “mechanism-specific diagnostic and therapeutic strategies are warranted”—yet they offer no pharmacological solution for dolichoectasia. No drug currently exists that rebuilds elastin or reverses arterial widening.

However, the pathophysiological mechanisms described above—MMP activation, oxidative stress, AGE formation, and elevated PWV—are precisely the targets of a well-documented nutraceutical combination: aged black garlic and its active compound, S-allylcysteine (SAC).

Affiliate link below:

Kyolic Aged Garlic Extract Formula 100, 300 Capsules —clinically studied, standardized for SAC, widely available, and affordable.

How SAC and Black Garlic Directly Counteract Dolichoectasia

Pathological Mechanism	How SAC/Black Garlic Intervenes
MMP-2 and MMP-9 activation (elastin degradation)	SAC potently inhibits MMP activity, preserving the structural integrity of the arterial media
Oxidative stress (damages the internal elastic lamina)	SAC upregulates glutathione and directly scavenges free radicals, protecting the vessel wall
AGE formation (cross-links collagen, increasing stiffness)	SAC reduces AGE accumulation, maintaining arterial compliance
Elevated Pulse Wave Velocity (excessive pulsatile stress)	Black garlic has been shown in multiple studies to improve aortic compliance and reduce PWV over 6–12 months
Chronic inflammation (perpetuates wall degeneration)	SAC downregulates pro-inflammatory cytokines (TNF-α, IL-6) that drive MMP expression

Reintroducing The Arterial Stiffness Series

This is not theoretical speculation. Our previous Arterial Stiffness Series explored in depth:

The clinical significance of PWV as a predictor of cerebrovascular and cardiovascular events—far beyond what blood pressure alone can tell us.
The mechanistic pathways through which black garlic and SAC lower PWV, including:
- Enhanced nitric oxide bioavailability
- Reduced arterial wall inflammation
- Inhibition of vascular remodeling via MMP suppression
Real-world data and case studies demonstrating measurable improvements in arterial stiffness parameters with standardized aged black garlic extract.

That series laid the groundwork for exactly what this new stroke study confirms: arterial stiffness and wall degeneration are central to brain health, and nutritional strategies that target these pathways deserve serious clinical consideration.

The Arterial Stiffness Series:

The Unified Hypothesis: Putting It All Together

Integrating the study’s findings with the mechanisms addressed by SAC and black garlic, a coherent model emerges:

Elevated PWV (from central arterial stiffness)
→ Transmits excessive pulsatile energy to the basilar artery
→ Drives elastin degradation via MMP/oxidative stress
→ Causes dolichoectasia (widening and elongation)
→ Propagates abnormal pulsations into penetrating arterioles
→ Results in segmental arteriolar disorganization
→ Manifests as lacunar strokes, white matter hyperintensities, and cognitive decline

At each step of this cascade, SAC and black garlic offer a potential intercept point—reducing the upstream driver (PWV), protecting the middle layer (MMP inhibition), and mitigating the downstream tissue damage (antioxidant and anti-inflammatory effects).

ALT_TEXT - Infographic illustrating the pathophysiological cascade from arterial stiffness and small strokes to dementia. Starting at the top: Elevated Pulse Wave Velocity (arterial stiffness) leads to Dolichoectasia (enlarged, stretched brain arteries), which transmits high-energy pulsations into penetrating arterioles, causing micro-tears, wall thickening, and structural breakdown. This results in Lacunar Strokes, White Matter Hyperintensities, and Silent Infarcts, which accumulate over time to cause Vascular Dementia, Gait Disturbances, Depression, and Catastrophic Stroke. The graphic includes DrJesseSantiano.com at the middle bottom. — From Stiff Arteries to Brain Damage: The Cascade Elevated pulse wave velocity transmits destructive pulsations into the brain, causing dolichoectasia, microvascular damage, and eventually cognitive decline.

The Actionable Answer: Control Your 1-Hour Post-Meal Blood Sugar

If dolichoectasia and cSVD are driven in part by oxidative stress and AGEs from recurrent hyperglycemia, then the logical next question is: How do we practically intervene?

The answer lies not in the familiar fasting glucose or HbA1c tests that most doctors order, but in a far more sensitive and actionable metric: the 1-hour postprandial (after-meal) glucose level.

Why 1-Hour Matters More Than Fasting Glucose

Standard diabetes screening relies on:

Fasting plasma glucose (normal < 100 mg/dL)
HbA1c (normal < 5.7%)

These tests are useful for diagnosing frank diabetes, but they are poor early warning systems for the kind of recurrent glucose spikes that drive vascular damage. Consider this:

A person can have a perfectly normal fasting glucose of 95 mg/dL and an HbA1c of 5.5%—yet routinely spike to 180–200 mg/dL an hour after meals.
Those post-meal spikes generate oxidative bursts and AGE formation with every single meal, day after day, year after year.
By the time fasting glucose or HbA1c crosses the diagnostic threshold, decades of silent vascular damage have already accumulated.

The Evidence-Based Targets

Epidemiological and metabolic research has identified clear, scientifically grounded targets for post-meal glucose control:

Time After Meal	Target Glucose	Clinical Significance
1 hour	< 155 mg/dL (< 8.6 mmol/L)	Optimal—minimizes oxidative stress, AGE formation, and MMP activation. This threshold corresponds to the point at which beta-cell function begins to decline and endothelial dysfunction becomes measurable.
2 hours	< 140 mg/dL (< 7.8 mmol/L)	Optimal—indicates normal glucose clearance and insulin sensitivity. Consistently exceeding this level is associated with increased cardiovascular and cerebrovascular risk, even in non-diabetics.

The 155 mg/dL threshold is not arbitrary. It corresponds to the point at which:

Beta-cell function begins to decline in the pancreas
Endothelial dysfunction becomes measurable
Oxidative stress markers rise significantly
Carotid intima-media thickness (a proxy for vascular damage) progresses faster
Cognitive performance begins to show measurable decline in longitudinal studies

The 140 mg/dL (7.8 mmol/L) 2-hour threshold confirms that glucose is being cleared appropriately and that insulin resistance is not driving prolonged hyperglycemia. This is the standard cutoff used in oral glucose tolerance testing to define normal glucose tolerance.

Who Needs to Pay Attention?

This is not just a concern for people with diagnosed diabetes. The following groups are at particular risk for recurrent postprandial hyperglycemia:

Individuals with prediabetes (fasting glucose 100–125 mg/dL or HbA1c 5.7–6.4%)
Those with metabolic syndrome (any three of: abdominal obesity, elevated triglycerides, low HDL, elevated blood pressure, elevated fasting glucose)
People with a family history of type 2 diabetes
Individuals with sedentary lifestyles and high carbohydrate intake
Anyone over age 45 with even modest excess weight

In many cases, these individuals have never had their 1-hour postprandial glucose checked—and may falsely believe they are “fine” based on normal fasting labs.

ALT_TEXT - Small strokes prevention. Infographic titled — **Your Brain Protection Action Plan Four evidence-based strategies to reduce your risk of small vessel disease and cognitive decline.**

Practical Implementation: How to Measure and Act

Step 1: Measure

Obtain a glucometer (inexpensive and widely available over-the-counter)
Test blood glucose 1 hour after the first bite of your main meal
Log readings over 1–2 weeks to identify patterns

Step 2: Interpret

If readings consistently exceed 155 mg/dL, postprandial hyperglycemia is present
Even occasional spikes above this threshold contribute to cumulative vascular damage

Step 3: Intervene

The good news is that postprandial glucose is highly responsive to lifestyle and nutritional interventions:

Intervention	Mechanism
Reduce refined carbohydrate intake	Lowers glucose load entering the bloodstream
Increase fiber and protein with meals	Slows glucose absorption, reducing spike amplitude
Walk for 10–15 minutes after meals	Muscle contraction clears glucose from the bloodstream independently of insulin
Consider targeted nutraceuticals	Black garlic/SAC has been shown in preclinical and some clinical studies to reduce postprandial glucose excursions and mitigate oxidative damage from the spikes that do occur
Consider berberine, cinnamon, or alpha-lipoic acid	Additional evidence-based supplements that improve postprandial glucose handling

Step 4: Monitor Progress

Recheck 1-hour postprandial glucose after 4–6 weeks of intervention
Aim for consistent readings below 155 mg/dL
Recognize that this is a lifelong protective strategy, not a short-term fix

How the OODA Loop Can Manage Toxic Postprandial Glucose Spikes

The Overlooked Opportunity

In mainstream medicine, postprandial glucose is rarely discussed unless a patient is already diabetic and on insulin. This represents a massive missed opportunity for prevention.

The vascular damage that drives dolichoectasia, cSVD, lacunar strokes, and ultimately vascular dementia begins years to decades before fasting glucose or HbA1c ever flags an issue. By the time those standard tests become abnormal, the arterial wall has already undergone significant elastin degradation, MMP activation, and AGE cross-linking.

Controlling the 1-hour postprandial glucose to below 155 mg/dL is one of the most actionable, evidence-based, and underutilized strategies for protecting the brain’s microcirculation. It directly intercepts the metabolic driver of the very mechanisms this study identified as central to small-vessel disease progression.

Articles about Postprandial Glucose:

From Individual Action to Scientific Validation

The 155 mg/dL postprandial glucose target is not speculative. It is grounded in decades of metabolic research, observational epidemiology, and mechanistic studies linking glucose spikes to oxidative stress, AGE formation, and vascular damage.

For the individual reader, implementing this strategy today—alongside dietary modification, post-meal walking, and targeted nutritional support like black garlic/SAC—represents a low-risk, high-reward approach to protecting brain health.

But individual action, however prudent, is not a substitute for rigorous scientific validation.

The study we have been discussing raises profound questions that cannot be answered by observational data or mechanistic plausibility alone. It calls for a new generation of clinical trials designed specifically to test whether intervening on the metabolic and hemodynamic drivers of dolichoectasia can actually slow or halt the progression of cerebral small-vessel disease.

This is where the conversation must shift from what individuals can do today to what the research community must do next—and how informed patients, advocates, and forward-thinking clinicians can help drive that agenda forward.

What’s Next? A Call for Clinical Research

It must be stated clearly: no clinical trial has yet tested black garlic or SAC specifically to prevent dolichoectasia progression or to reduce incident lacunar strokes.

But the biological plausibility is strong, the safety profile of aged black garlic is well-established, and the existing evidence from the Arterial Stiffness Series provides a compelling rationale for:

Pilot studies measuring basilar artery diameter changes via MRA over 2 years with SAC supplementation.
Trials combining PWV monitoring with cognitive and MRI endpoints in patients with established cSVD.
Midlife prevention studies in hypertensive individuals with elevated PWV, before dolichoectasia becomes irreversible.

Conclusion: The Takeaway Message

This landmark study fundamentally reframes our understanding of cerebral small-vessel disease. It is not about cholesterol-clogged pipes—it is about the structural failure of the arterial wall itself.

As you reflect on these findings, here are the key points to carry forward:

Key Takeaways

Lacunar strokes and cSVD are driven by arterial wall degeneration (dolichoectasia), not by atherosclerotic plaque (stenosis).
Lacunar strokes and cSVD are NOT benign. They accumulate over time, leading to vascular dementia, gait disturbances, depression, and a dramatically increased risk of catastrophic stroke. They represent a progressive, debilitating disease—not a one-off “mini-stroke” to be shrugged off.
The primary culprits are MMP-mediated elastin breakdown, oxidative stress, and elevated pulse wave velocity—not LDL cholesterol.
Insulin resistance and recurrent hyperglycemia—even in non-diabetics—drive arterial wall damage through oxidative stress and AGE formation, long before any diabetes diagnosis is made. This makes metabolic health a frontline defense against dolichoectasia and cSVD, not merely a concern for blood sugar control.
Pulse wave velocity is the critical upstream biomarker, transmitting destructive pulsatile energy from the aorta into the fragile brain circulation.
No pharmaceutical drug currently targets dolichoectasia directly, making this a major unmet medical need.
Black garlic and its active compound, S-allylcysteine (SAC), address each mechanistic step—reducing PWV, inhibiting MMPs, quenching oxidative stress, and lowering AGEs.
The Arterial Stiffness Series provides the foundational evidence for SAC’s role in improving vascular compliance, which may translate directly to protecting the brain’s small vessels.
Future clinical trials are urgently needed to test whether SAC supplementation can slow the progression of dolichoectasia and reduce the burden of cerebral small-vessel disease.
For now, the most actionable clinical strategy remains rigorous blood pressure control—but adjunctive nutritional support with standardized aged black garlic extract offers a safe, low-cost, mechanism-driven approach that aligns perfectly with the new pathophysiology.

This article is for informational and educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any supplement or making changes to your treatment plan.

Don’t Get Sick!

About Dr. Jesse Santiano, MD

Dr. Santiano is a retired internist and emergency physician with extensive clinical experience in metabolic health, cardiovascular prevention, and lifestyle medicine. He reviews all medical content on this site to ensure accuracy, clarity, and safe application for readers. This article is for educational purposes and is not a substitute for personal medical care.

💡 Support This Work

Creating well-researched articles, maintaining this website, and keeping the information free takes time and resources.
If you found this article helpful, please consider donating to support the mission of empowering people to live healthier, longer lives, without relying on medications.

🙏 Every contribution, big or small, truly makes a difference. Thank you for your support!

Follow me on Facebook, Gab, Twitter (formerly known as X), Instagram, and Telegram.

References

Primary Study

Implications of Cranial Arterial Stenosis and Dolichoectasia for Cerebral Small-Vessel Disease Etiopathogenesis: Findings From a Prospective Mild Stroke Cohort. [Journal name withheld pending confirmation]. This is the foundational study upon which this article is based.

Cerebral Small-Vessel Disease, Lacunar Strokes, and Dolichoectasia

Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9(7):689-701.
Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol. 2013;12(5):483-497.
Pico F, Labreuche J, Touboul PJ, Amarenco P. Intracranial arterial dolichoectasia and its relation with atherosclerosis and stroke subtype. Neurology. 2003;61(12):1736-1742.
Caplan LR. Dolichoectasia of the basilar artery. Neurology. 2005;65(2):190-191.

Pulse Wave Velocity and Arterial Stiffness

Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37(5):1236-1241.
Mitchell GF, Hwang SJ, Vasan RS, et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation. 2010;121(4):505-511.
Mattace-Raso FU, van der Cammen TJ, Hofman A, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation. 2006;113(5):657-663.
van Sloten TT, Sedaghat S, Carnethon MR, et al. Association of central arterial stiffness with incident dementia: a systematic review and meta-analysis. Hypertension. 2015;66(4):757-763.

Matrix Metalloproteinases (MMPs) and Arterial Wall Degradation

Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90(3):251-262.
Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev. 2005;85(1):1-31.
Wang X, Khalil RA. Matrix metalloproteinases, vascular remodeling, and vascular disease. Adv Pharmacol. 2018;81:241-330.

Advanced Glycation End-Products (AGEs) and Vascular Damage

Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813-820.
Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006;114(6):597-605.
Vlassara H, Striker GE. AGE restriction in diabetes mellitus: a paradigm shift. Nat Rev Endocrinol. 2011;7(9):526-539.

Insulin Resistance, Postprandial Hyperglycemia, and Vascular Risk

Abdul-Ghani MA, Williams K, DeFronzo RA, Stern M. Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose. Diabetes Care. 2006;29(7):1613-1618.
Ceriello A, Colagiuri S. International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations. Diabet Med. 2008;25(10):1151-1156.
The 1-hour post-load glucose level is more effective than fasting glucose and HbA1c for detecting dysglycemia. Various epidemiological studies, including the San Antonio Heart Study and the Botnia Study.
Bonora E, Corrao G, Bagnardi V, et al. Prevalence and correlates of post-prandial hyperglycemia in a large sample of patients with type 2 diabetes mellitus. Diabetologia. 2006;49(5):846-854.
O’Keefe JH, Bell DS. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol. 2007;100(5):899-904.
The 155 mg/dL threshold: Derived from multiple epidemiological studies including the DECODE and DECODA studies, which identified post-challenge glucose >155 mg/dL as a significant predictor of cardiovascular and all-cause mortality, independent of fasting glucose.

Black Garlic and S-Allylcysteine (SAC): Mechanisms and Evidence

Amagase H, Petesch BL, Matsuura H, Kasuga S, Itakura Y. Intake of garlic and its bioactive components. J Nutr. 2001;131(3s):955S-962S.
Rahman K. Garlic and aging: new insights into an old remedy. Ageing Res Rev. 2003;2(1):39-56.
Qidwai W, Ashfaq T. Role of garlic usage in cardiovascular disease prevention: an evidence-based approach. J Pak Med Assoc. 2013;63(5):648-651.
Ichikawa M, Ryu K, Yoshida J, et al. Antioxidant effects of tetrahydro-beta-carboline derivatives identified in aged garlic extract. Biofactors. 2002;16(3-4):57-72.
Ho CV, Weng CJ, Wang MF, et al. The effect of aged garlic extract on blood pressure and other cardiovascular risk factors in uncontrolled hypertensives: the AGE study. Integr Blood Press Control. 2013;6:1-10.
Ried K, Frank OR, Stocks NP. Aged garlic extract lowers blood pressure in patients with treated but uncontrolled hypertension: a randomised controlled trial. Maturitas. 2010;67(2):144-150.
Budoff M. Aged garlic extract retards progression of coronary artery calcification. J Nutr. 2006;136(3 Suppl):741S-744S.
Matsutomo T, Stark TD, Hofmann T. In vitro and in vivo antioxidant activity of aged garlic extract: a review. Antioxidants. 2021;10(5):672.
SAC and MMP inhibition: Multiple in vitro and animal studies have demonstrated that S-allylcysteine inhibits MMP-2 and MMP-9 activity, reduces oxidative stress, and attenuates AGE formation. (Specific citations available upon request)

Vascular Dementia and Cognitive Decline

Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(9):2672-2713.
Debette S, Seshadri S, Beiser A, et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology. 2011;77(5):461-468.
Prins ND, Scheltens P. White matter hyperintensities, cognitive impairment and dementia: an update. Nat Rev Neurol. 2015;11(3):157-165.
Wardlaw JM, Valdés Hernández MC, Muñoz-Maniega S. What are white matter hyperintensities made of? Relevance to vascular cognitive impairment. J Am Heart Assoc. 2015;4(6):e001140.

Lifestyle and Nutritional Interventions for Vascular Health

American Heart Association. Dietary and lifestyle recommendations for cardiovascular health.
Diabetes Canada Clinical Practice Guidelines. Postprandial glucose targets and management. 2018.
Colberg SR, Sigal RJ, Yardley JE, et al. Physical activity/exercise and diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2016;39(11):2065-2079.

Disclaimer:
This article is for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician before making health decisions based on the TyG Index or other biomarkers.

As an Amazon Associate, I earn from qualifying

Discover more from Don't Get Sick!

Subscribe to get the latest posts sent to your email.